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Plerixafor allows for rapid mobilization of hematopoietic
stem cells (HSCs) by disrupting the interaction of HSC re-
ceptor CXCR4 and bone marrow stromal cytokine SDF-1
alpha. When combined with granulocyte colony stimulating
factor (G-CSF) with or without chemotherapy, rates of suc-
cessful mobilization are increased in patients who have
previously failed to mobilize or have traits predictive of
failure. Current package labeling for plerixafor states that
leukapharesis (LP) should begin 10-11 hours post adminis-
tration, the time at which peak peripheral blood (PB) CD34+
cell counts have been observed. Phase I data in healthy vol-
unteers shows that peak PB CD34+ cell count is dose
dependent and that counts increase in a linear fashion be-
tween hours 1,3,6 and 9. Studies in HLA-matched sibling
donors have shown that minimum required yield for trans-
plant can be reached when LP begins 4 hours after plerixafor
injection. In our institution, due to time constraints, we
follow a model consistent with these previous studies and
begin LP 4-6 hours after plerixafor injection. In order to
assess efﬁcacy of this timing in patients undergoing autolo-
gous stem cell transplant (autoSCT), we completed a retro-
spective chart review of 43 patients; 25 with lymphoma and
18 with multiple myeloma (MM). The median percent
change in PB CD34+ cell count, prior to 1stLP, was 19.9% in
lymphoma and 13.45% in MM. 95% of patients reached the
minimumyield required for autoSCT in 4 days. One patient
with MM and one patient with lymphoma failed to collect
adequate levels of HSCs. The median total CD34+ yield was
4.33x106 and 6.73x106 in the lymphoma and MM groups
respectively. All but ﬁve patients proceeded to autoSCT.
Among the 38 patients that remained eligible for autoSCT,
themedian number of days for ANC and platelet engraftment
was 11 and 22 respectively. These results are comparable to
historical data, thus showing that high risk patients can
collect an adequate number of stem cells, in an expected
period of time, with good engraftment results using an
alternative plerixafor mobilization schedule.135
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Background: CD34+ cell-doses given during autologous
stem cell transplantation (ASCT) for multiple myeloma (MM)
patients (pts) can vary between pts depending on ability to
mobilize CD34+ cells and amount of CD34+ cells/kg collected
during the apheresis procedure. Published retrospective
studies suggest that absolute lymphocyte count (ALC) re-
covery may be a predictor of overall survival (OS), progres-
sion free survival (PFS), and infectious complications in ASCT.
It is unclear whether there is an optimal CD34+ cell-dose that
correlates with a shorter time to ALC recovery, possiblydecreasing infectious complications, and potentially
increasing time to relapse.
Methods: A retrospective analysis of ALC recovery was per-
formed on 12 consecutive MM pts who had undergone ASCT
from 1/2012 to 1/2013 at the University of Virginia to
determine if a relationship existed between CD34+ cell-dose
given during ASCT and ALC recovery. For each pt, number/
type of infection and ALCs were collected for the ﬁrst 100
days post-ASCT. OS and PFS were also assessed for each pt.
Cox proportional hazard models were used to estimate the
association of CD34+ cell-dose infused with time to ALC re-
covery after ASCT. ALC recovery was deﬁned as the ﬁrst day
of three consecutive measurements for three different cutoff
values: ALC  800, ALC  1000, and ALC  1500. No
competing risks occurred; therefore, the log rank test sta-
tistic was used to assess the signiﬁcance of the association.
Results: Median age was 60 years (range from 45-71 years),
75% were male, 67% had IgG MM, and 92% had kappa light
chain restriction. Fifty-eight percent had ISS Stage I MM and
33% had ISS Stage III disease. The analysis revealed that a
higher CD34+ cell-dose given during ASCT showed a trend
toward faster ALC recovery, when deﬁned as ALC  800
(p¼.043) and ALC  1000 (p¼.052). No difference was seen
for ALC  1500. Median times to achieving ALC  800 and
ALC  1000 were 43 and 59 days, respectively for pts given
CD34+ cell-dose < 4x106 cells/kg; and were 18 and 19 days
for pts given CD34+ cell-dose > 4x106 cells/kg. All ﬁve pts
transplanted with a CD34+ cell-dose < 4x106 cells/kg
developed at least one bacterial infection. Only one of the
seven pts transplantedwith CD34+ cell-dose> 4x106 cells/kg
developed bacterial complications. Eighty-two percent of
bacterial infections (n¼11) occurred in pts given CD34+ cell-
dose < 4x106cells/kg. Median time of follow-up was 12
months (range from 9 to 20 months). Two pts have relapsed,
at 10 and 13months, post-ASCTand no deaths have occurred.
Conclusion: These preliminary results suggest that CD34+
cell-dose > 4x106 cells/kg given during ASCT for MMmay be
associated with shorter ALC recovery and lower rates of in-
fections. However, larger prospective trials with longer
follow-up are necessary to further deﬁne optimal CD34+ cell-
dose infusion for ASCT in MM pts in order to improve ALC
recovery.136
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Background: The role of radiological surveillance with
Positron Emission Tomography (PET) or Computed Tomog-
raphy (CT) after completion of chemotherapy in patients
with lymphoma is controversial. Prior studies have shown
conﬂicting results in regards to the beneﬁt of screening for
patients with lymphoma using CT or PET versus clinical
detection of relapse. What is not known is whether
